<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373046</url>
  </required_header>
  <id_info>
    <org_study_id>LX4211.1-117-NRM</org_study_id>
    <secondary_id>LX4211.117</secondary_id>
    <nct_id>NCT02373046</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets</brief_title>
  <official_title>A Phase 1, Randomized, Single-center, Open-label, 2-sequence, 2-period, Single-dose Crossover Study to Evaluate Bioequivalence (Pharmacokinetics) and to Compare Total 24-hour Urinary Glucose Excretion (Pharmacodynamics) When 400 mg LX4211 is Administered as a Single 400-mg Tablet and 2 × 200-mg Tablets in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single-center, open-label, 2-sequence, 2-period, single-dose, crossover
      study to assess the bioequivalence and the total 24-hour urinary glucose excretion (UGE) of
      400 mg LX4211 administered as a single 400-mg tablet compared to 2 × 200-mg tablets in
      healthy subjects under fasted conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Days 1 to 5, Days 9 to 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Glucose Excretion (UGE)</measure>
    <time_frame>Day 1, Day 9</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure># of Adverse Events</measure>
    <time_frame>Day 1-Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 × 400-mg LX4211 tablet (fasted conditions)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 × 200-mg LX4211 tablets (fasted conditions)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX4211</intervention_name>
    <description>Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX4211</intervention_name>
    <description>Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects ≥18 to ≤55 years of age

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  Presence of clinically significant physical, laboratory, or ECG findings that, in the
             opinion of the Investigator and/or Sponsor, may interfere with any aspect of study
             conduct or interpretation of results

          -  Existence of any surgical or medical condition that might interfere with the
             absorption, distribution, metabolism, or excretion of LX4211

          -  History of renal disease, or significantly abnormal kidney function test at Screening

          -  History of hepatic disease, or significantly abnormal liver function tests at
             Screening

          -  History of any clinically relevant psychiatric, renal, hepatic, pancreatic, endocrine,
             cardiovascular, neurological, hematological, or GI abnormality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suman Wason, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

